Treating age-related multimorbidity:the drug discovery challenge

Patients with multimorbidities have shorter life expectancy and their clinical management is more complex and expensive for healthcare systems currently focused on treating single diseases. Given that age is the major risk factor for multimorbidity, the challenge of treating these patients will only increase in coming years. Here, we review the case for targeting the core processes that drive the ageing phenotype as a novel pharmaceutical approach to multimorbidity. There is growing evidence that targeting ageing mechanisms can reduce or delay age-related diseases in animal models, and the first reports of clinical trials are now appearing. Although these trials currently focus on repurposed drugs, we propose several novel targets that would more specifically target ageing processes and thereby reduce multimorbidity and polypharmacy in future generations

Tests of analytical hadronisation models using event shape moments in {\epem} annihilation

Predictions of analytical models for hadronisation, namely the dispersive model, the shape function and the single dressed gluon approximation, are compared with moments of hadronic event shape distributions measured in \epem annihilation at centre-of-mass energies between 14 and 209 GeV. In contrast to Monte Carlo models for hadronisation, analytical models require to adjust only two universal parameters, the strong coupling and a second quantity parametrising nonperturbative corrections. The extracted values of as are consistent with the world average and competitive with previous measurements. The variance of event shape distributions is compared with predictions given by some of these models. Limitations of the models, probably due to unknown higher order corrections, are demonstrated and discussed.Comment: Ref.s [19,36] added and footnote 1 adjuste